Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fovea Pharmaceuticals has entered into a collaborative research agreement with Genzyme Corporation to develop gene-related therapies using Fovea selected targets and Genzyme gene delivery technologies.
Subscribe to our email newsletter
The alliance is anchored around Fovea’s proprietary high content technology platform that allows the identification of new targets involved in photoreceptor degeneration in retinal dystrophies.
Both companies declined to disclose financial terms. The partnership intends to utilize Fovea’s scientific, clinical and pharmaceutical expertise in retinal diseases and Genzyme’s know-how in protein production and gene delivery to offer customized solutions for the understanding of the disease mechanisms, to develop new therapeutic strategies to prevent or reduce the severity of blindness.
Bernard Gilly, chairman and CEO of Fovea, said: “This first research partnership signed with Genzyme demonstrates the interest of our proprietary discovery platform. This collaboration underscores the substantial opportunity that our expertise in retinal diseases and unique platform provide to increase the efficiency and probability of success in ophthalmology drug discovery and development.”